<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C01B&quot;,&quot;href&quot;:&quot;atc/C01B.md&quot;},{&quot;label&quot;:&quot;disopyramide&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Disopyramide_Bryson1978_reference&quot;,&quot;label&quot;:&quot;Bryson_1978_reference&quot;,&quot;href&quot;:&quot;drugs/drug_disopyramide/Disopyramide_Bryson1978_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Disopyramide_Aso2001_reference&quot;,&quot;label&quot;:&quot;Aso_2001_reference&quot;,&quot;href&quot;:&quot;drugs/drug_disopyramide/Disopyramide_Aso2001_reference.md&quot;,&quot;status&quot;:&quot;built, not shipped&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Disopyramide_Pedersen1986_reference&quot;,&quot;label&quot;:&quot;Pedersen_1986_reference&quot;,&quot;href&quot;:&quot;drugs/drug_disopyramide/Disopyramide_Pedersen1986_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Disopyramide_Yukawa2005_reference&quot;,&quot;label&quot;:&quot;Yukawa_2005_reference&quot;,&quot;href&quot;:&quot;drugs/drug_disopyramide/Disopyramide_Yukawa2005_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Disopyramide_Bonde1989_reference&quot;,&quot;label&quot;:&quot;Bonde_1989_reference&quot;,&quot;href&quot;:&quot;drugs/drug_disopyramide/Disopyramide_Bonde1989_reference.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Disopyramide_Burk1983_reference&quot;,&quot;label&quot;:&quot;Burk_1983_reference&quot;,&quot;href&quot;:&quot;drugs/drug_disopyramide/Disopyramide_Burk1983_reference.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false}]"></div>

# disopyramide

- **generic name:** disopyramide
- **ATC codes:** `C01BA03`
- **DrugBank:** [DB00280](https://go.drugbank.com/drugs/DB00280) · **PubChem:** [CID 3114](https://pubchem.ncbi.nlm.nih.gov/compound/3114)
- **molar mass:** 339.4745 g/mol (C21H29N3O) — DrugBank
- **groups:** approved, investigational

## About

**Description.** A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

**Indication.** For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-26 10:58 | 3:18 | 2/2/2 | 3/0/0 | 0/0/0 | 55,636/3,368 | ollama / qwen3.8:27b-mtp-q8_0 | 23 | 22/1 | 6/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.571). The first reading is what the record holds.">cross-check: disputed</span> | [Bryson_1978_reference](drugs/drug_disopyramide/Disopyramide_Bryson1978_reference.md) | ▶ model + simulator | 1-compartment, IV | 2 | Bryson SM et al., Disopyramide serum and pharmacologic ef…, British journal of clinical… (1978) | [10.1111/j.1365-2125.1978.tb04605.x](https://doi.org/10.1111/j.1365-2125.1978.tb04605.x) |
| <span class="pk-badge pk-badge--orange">built, not shipped</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.75). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: model_quarantined: Cl, ka, Tlag left at base-class defaults</sub><br><sub>route_to: `scholar`</sub> | [Aso_2001_reference](drugs/drug_disopyramide/Disopyramide_Aso2001_reference.md) | held back | 1-compartment, oral | 2 | Aso R et al., Population pharmacokinetics, protein bi…, International journal of cl… (2001) | — |
| <span class="pk-badge pk-badge--orange">needs review</span><br><sub>blocking: disposition incomplete — only clearance/elimination extracted — the engineer ne…</sub><br><sub>route_to: `human_review`</sub> | [Pedersen_1986_reference](drugs/drug_disopyramide/Disopyramide_Pedersen1986_reference.md) | held back | 1-compartment, IV | 2 | Pedersen LE et al., The pharmacokinetics and protein bindin…, Acta pharmacologica et toxi… (1986) | [10.1111/j.1600-0773.1986.tb00110.x](https://doi.org/10.1111/j.1600-0773.1986.tb00110.x) |
| <span class="pk-badge pk-badge--orange">needs review</span><br><sub>blocking: disposition incomplete — only volume extracted — the engineer needs both; the m…</sub><br><sub>route_to: `human_review`</sub> | [Yukawa_2005_reference](drugs/drug_disopyramide/Disopyramide_Yukawa2005_reference.md) | held back | 1-compartment, oral | 2 | Yukawa E et al., Population pharmacokinetic investigatio…, Journal of clinical pharmac… (2005) | [10.1111/j.1365-2710.2005.00668.x](https://doi.org/10.1111/j.1365-2710.2005.00668.x) |
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: missing key parameters — none reported by this paper (the values present come f…</sub><br><sub>route_to: `human_review`</sub> | [Bonde_1989_reference](drugs/drug_disopyramide/Disopyramide_Bonde1989_reference.md) | held back | 1-compartment, IV | 1 | Bonde J et al., Disposition kinetics of disopyramide in…, Pharmacology & toxicology (1989) | [10.1111/j.1600-0773.1989.tb00677.x](https://doi.org/10.1111/j.1600-0773.1989.tb00677.x) |
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: missing key parameters — none reported by this paper</sub><br><sub>route_to: `human_review`</sub> | [Burk_1983_reference](drugs/drug_disopyramide/Disopyramide_Burk1983_reference.md) | held back | 1-compartment, IV | 0 | Burk M et al., Disopyramide kinetics in renal impairme…, Clinical pharmacology and t… (1983) | [10.1038/clpt.1983.176](https://doi.org/10.1038/clpt.1983.176) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_APD90](drugs/drug_disopyramide/pd_Luo_2017_APD90.md) | name ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_Dominant_frequency](drugs/drug_disopyramide/pd_Luo_2017_Dominant_frequency.md) | name ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_ERP](drugs/drug_disopyramide/pd_Luo_2017_ERP.md) | name ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_QT_interval](drugs/drug_disopyramide/pd_Luo_2017_QT_interval.md) | name ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_T_wave_amplitude](drugs/drug_disopyramide/pd_Luo_2017_T_wave_amplitude.md) | name ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_Temporal_vulnerability_window](drugs/drug_disopyramide/pd_Luo_2017_Temporal_vulnerability_window.md) | name ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_Transmural_AP_heterogeneity_V](drugs/drug_disopyramide/pd_Luo_2017_Transmural_AP_heterogeneity_V.md) | name ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_2_APD90](drugs/drug_disopyramide/pd_Luo_2017_2_APD90.md) | APD90 ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_2_CV](drugs/drug_disopyramide/pd_Luo_2017_2_CV.md) | Conduction velocity ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_2_ERP](drugs/drug_disopyramide/pd_Luo_2017_2_ERP.md) | ERP ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_2_QT](drugs/drug_disopyramide/pd_Luo_2017_2_QT.md) | QT interval ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_2_S2_min](drugs/drug_disopyramide/pd_Luo_2017_2_S2_min.md) | Minimal length of S2 ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Luo_2017_2_VW](drugs/drug_disopyramide/pd_Luo_2017_2_VW.md) | Vulnerability window ← quinidine · stimulation effect | — | Luo (2017) | — |
| <span class="pk-badge pk-badge--green">extracted</span> | [Whiting_1980_QT](drugs/drug_disopyramide/pd_Whiting_1980_QT.md) | QT prolongation ← disopyramide · delayed effect through an effect compartment | — | Whiting B et al., Quantitative analysis of the disopyrami…, British journal of clinical… (1980) | [10.1111/j.1365-2125.1980.tb04799.x](https://doi.org/10.1111/j.1365-2125.1980.tb04799.x) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=disopyramide) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| distribution | blood | `ORM1` other/unknown, `ORM2` binder | DrugBank actor |
| metabolism | liver | `CYP1A2` substrate, `CYP3A4` substrate, `SLC22A1` inhibitor | DrugBank actor |
| metabolism | small intestine | `CYP3A4` substrate | DrugBank actor |
| excretion | kidney | `SLC22A2` inhibitor | DrugBank actor |

<sub>Actors without a tissue in the table: CHRM1 (target), CHRM2 (target), CHRM3 (target), KCND2 (inhibitor), KCND3 (inhibitor), KCNH2 (inhibitor), SCN5A (inhibitor).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 27 matched, 20 returned
- **screened:** 26  ·  **relevant:** 5
- **records:** 6  ·  extracted 1  ·  needs_review 3  ·  rejected 2  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_7 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Bonde_1989.pdf` | Bonde J et al., Disposition kinetics of disopyramide in…, Pharmacology & toxicology (1989) | popPK | 10 | [10.1111/j.1600-0773.1989.tb00677.x](https://doi.org/10.1111/j.1600-0773.1989.tb00677.x) | [2771866](https://pubmed.ncbi.nlm.nih.gov/2771866) | The paper describes a compartmental PK model for disopyramide, but the specific numeric parameter values (CL, V, t1/2) are not present in the provided evidence text. |
| `Yukawa_2005.pdf` | Yukawa E et al., Population pharmacokinetic investigatio…, Journal of clinical pharmac… (2005) | popPK | 10 | [10.1111/j.1365-2710.2005.00668.x](https://doi.org/10.1111/j.1365-2710.2005.00668.x) | [15985054](https://pubmed.ncbi.nlm.nih.gov/15985054) | The paper reports a population PK model for disopyramide with explicit numeric values for clearance, volume of distribution, and absorption rate constant in the text. |
| `Burk_1983.pdf` | Burk M et al., Disopyramide kinetics in renal impairme…, Clinical pharmacology and t… (1983) | popPK | 9 | [10.1038/clpt.1983.176](https://doi.org/10.1038/clpt.1983.176) | [6883909](https://pubmed.ncbi.nlm.nih.gov/6883909) | The study reports quantitative PK parameters (clearance, volume) for disopyramide, but the specific numeric values are not present in the provided abstract text. |
| `Nagura_1991.pdf` | Nagura Y et al., Pharmacokinetics and optimum dose of di…, Nihon Jinzo Gakkai shi (1991) | popPK | 9 | not captured | [1895553](https://pubmed.ncbi.nlm.nih.gov/1895553) | The study reports quantitative pharmacokinetic parameters (half-life, Tmax, Cmax) for disopyramide in humans using a two-compartment model, with specific numeric values provided in the text. |
| `Pedersen_1986.pdf` | Pedersen LE et al., The pharmacokinetics and protein bindin…, Acta pharmacologica et toxi… (1986) | popPK | 9 | [10.1111/j.1600-0773.1986.tb00110.x](https://doi.org/10.1111/j.1600-0773.1986.tb00110.x) | [3716823](https://pubmed.ncbi.nlm.nih.gov/3716823) | The study reports quantitative PK parameters (clearance, half-life) for disopyramide in pigs, but specific values for volume of distribution and intercompartmental clearance are not explicitly listed in the provided text. |
| `Thibonnier_1984.pdf` | Thibonnier M et al., Pharmacokinetic-pharmacodynamic analysi…, Journal of pharmacokinetics… (1984) | popPK | 9 | [10.1007/BF01059552](https://doi.org/10.1007/BF01059552) | [6398364](https://pubmed.ncbi.nlm.nih.gov/6398364) | The paper describes a pharmacokinetic study of disopyramide with a compartmental model, but the specific numeric parameter values are not present in the provided evidence. |
| `Kelman_1980.pdf` | Kelman AW et al., Modeling of drug response in individual…, Journal of pharmacokinetics… (1980) | popPK | 8 | [10.1007/BF01065188](https://doi.org/10.1007/BF01065188) | [7431218](https://pubmed.ncbi.nlm.nih.gov/7431218) | The paper describes a pharmacokinetic modeling study for disopyramide, but the provided evidence contains only the abstract/methodology description without any specific numeric parameter values. |

<sub>queue written 2026-09-19T15:04:02.358092+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Bonde_1989 | relevant | 10 | 0 | The paper describes a compartmental PK model for disopyramide, but the specific numeric parameter values (CL, V, t1/2) are not present in the provided evidence text. |
| popPK | Burk_1983 | relevant | 9 | 2 | The study reports quantitative PK parameters (clearance, volume) for disopyramide, but the specific numeric values are not present in the provided abstract text. |
| popPK | Hanada_1999 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of cisplatin, with disopyramide serving only as a co-administered agent to test for interactions, and no PK parameters for disopyramide are reported. |
| popPK | Hanada_1999_2 | irrelevant | 2 | 0 | The study focuses on pharmacodynamic interactions (QT prolongation) and explicitly states that erythromycin did not affect the pharmacokinetics of disopyramide, without reporting specific quantitative PK parameter values (CL, V, etc.) for disopyramide. |
| popPK | Horie_2001 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of insulin release and K(ATP) channel inhibition, reporting no pharmacokinetic disposition parameters for disopyramide. |
| popPK | Kelman_1980 | relevant | 8 | 0 | The paper describes a pharmacokinetic modeling study for disopyramide, but the provided evidence contains only the abstract/methodology description without any specific numeric parameter values. |
| PD | Kelman_1980 | not_relevant | 4 | 0 | The text describes the methodology for individual-subject PK/PD modeling of disopyramide but does not provide any numeric PD parameters or data points in the provided snippet. |
| popPK | Luo_2017 | irrelevant | 0 | 0 | The paper is an in silico electrophysiology study modeling drug effects on ion channels and action potentials, not a pharmacokinetic study reporting disposition parameters like clearance or volume for disopyramide. |
| popPK | Luo_2017_2 | irrelevant | 0 | 0 | The paper is a computational electrophysiology study modeling ion channel effects, not a pharmacokinetic study, and reports no disposition parameters for disopyramide. |
| popPK | Miyazaki_2000 | irrelevant | 0 | 0 | The provided evidence contains only metadata and software version information, with no pharmacokinetic data or text regarding disopyramide. |
| PD | Miyazaki_2000 | not_relevant | 0 | 0 | The provided text is metadata for the GROBID software and does not contain any pharmacological data, PD models, or information regarding disopyramide. |
| popPK | Thibonnier_1984 | relevant | 9 | 0 | The paper describes a pharmacokinetic study of disopyramide with a compartmental model, but the specific numeric parameter values are not present in the provided evidence. |
| popPK | Virág_1998 | irrelevant | 0 | 0 | The study is an in-vitro electrophysiological investigation of potassium currents in rabbit myocytes and does not report pharmacokinetic disposition parameters. |
| popPK | Whiting_1980 | relevant | 9 | 2 | The paper is a PK/PD study of disopyramide that fits compartmental models, but the specific numeric PK parameters (CL, V, ka, half-life) are cited as being in "Table 1" which is not included in the provided evidence, whereas the available Table 5 contains only pharmacodynamic parameters (keq, slopes). |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-19 15:04 UTC</sub>
